Movement Disorder News and Research

Latest Movement Disorder News and Research

Exercise program improves symptoms of depression in patients with Parkinson's disease

A new study by a movement disorder neurologist at The Ohio State University Wexner Medical Center found that depression improved among patients with Parkinson's disease who participated in a long-term group exercise program.

10 Dec 2013

VISIUS iMRI and ClearPoint guidance platform make DBS surgery an option for children with dystonia

IMRIS Inc. and MRI Interventions, Inc. today announced that Cook Children's Medical Center in Fort Worth, Texas, is the first U.S. pediatric hospital to offer asleep deep brain stimulation surgery to children suffering from dystonia by utilizing the combination of MRI Interventions' ClearPoint Neuro Intervention System and an IMRIS VISIUS Surgical Theatre for real-time intraoperative image guidance and procedure visualization.

4 Dec 2013

Henry Ford offers electric stimulation of brain using FDA-approved device for hard-to-treat epilepsy cases

Because of its participation in a pivotal trial, Henry Ford Hospital will be the first in Michigan to offer electric stimulation of the brain using a newly FDA-approved device for hard-to-treat epilepsy cases.

21 Nov 2013

Boston Scientific gets CE Mark approval for Vercise Deep Brain Stimulation System

The Boston Scientific Corporation Vercise Deep Brain Stimulation System has received CE Mark approval for the treatment of intractable primary and secondary dystonia, a neurological movement disorder characterized by involuntary muscle contractions.

19 Nov 2013

InSightec: First patient treated in ExAblate Neuro Phase III pivotal trial for tremor

InSightec Ltd, the global leader in MR guided focused ultrasound, announced that the first patient has been treated as part of an ExAblate Neuro Phase III pivotal trial. The trial is a multicenter, double-blinded, randomized study to evaluate the efficacy and safety of treatment using the ExAblate Neuro in medication-refractory essential tremor patients.

11 Sep 2013

GLNT integrates video conferencing technology into Kinesia HomeView for Parkinson’s disease patients

Great Lakes NeuroTechnologies announced today they are launching commercialization and clinical studies to expand their telemedicine technology, Kinesia HomeView, for individuals with Parkinson’s disease by adding real-time video conferencing.

7 Sep 2013

Parkin protein plays key role in destruction of bacteria that cause tuberculosis

A protein at the center of Parkinson's disease research now also has been found to play a key role in causing the destruction of bacteria that cause tuberculosis, according to scientists led by UC San Francisco microbiologist and tuberculosis expert Jeffery Cox, PhD.

5 Sep 2013

Scientists identify new drugs that have potential to slow down progression of Parkinson's

New drugs which may have the potential to stop faulty brain cells dying and slow down the progression of Parkinson's, have been identified by scientists in a pioneering study which is the first of its kind.

4 Sep 2013

Alzheimer’s drug trial: an interview with Geoffrey Kempler, Chairman & CEO Prana Biotechnology

Approval for the IMAGINE trial was granted by the Austin Health Research Ethics Committee in November 2011, with the first patients dosed in March the following year. However, well before the trial was approved, PBT2 had already shown promise in significantly changing Abeta levels in spinal fluid while improving cognition in a previous 12-week trial conducted in 2006.

28 Aug 2013

Navidea Biopharmaceuticals signs SPA agreements with FDA for NAV5001 Phase 3 program

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that it has reached agreement with the U.S. Food and Drug Administration for two special protocol assessments for the Company's pivotal Phase 3 program with NAV5001 as an aid in the differential diagnosis of Parkinsonian Syndromes from non-Parkinsonian tremor.

23 Aug 2013

Researcher discovers potential explanation for shizophrenia symptoms

By observing the eye movements of schizophrenia patients while playing a simple video game, a University of British Columbia researcher has discovered a potential explanation for some of their symptoms, including difficulty with everyday tasks.

29 Jul 2013

Great Lakes NeuroTechnologies receives patent for Parkinson’s disease monitoring technology

Great Lakes NeuroTechnologies announced today they have received allowance of claims from the U.S. Patent Office for an application covering their system and method of stimulating the brain during sleep to treat movement disorder symptoms.

22 Jul 2013

Experts report lasting benefits of deep brain stimulation in patients with hereditary dystonia

In what is believed to be the largest follow-up record of patients with the most common form of hereditary dystonia - a movement disorder that can cause crippling muscle contractions - experts in deep brain stimulation report good success rates and lasting benefits.

20 Jun 2013

Research: Deep brain stimulation is associated with weight loss trend in morbidly obese patients

The first use of deep brain stimulation to the brain's so-called "feeding center" - the lateral hypothalamic area (LHA) - was associated with a weight loss trend in morbidly obese patients whose stimulation was tuned to increase metabolism with novel guidance from metabolic chamber data, according to a pilot study presented at the International Neuromodulation Society's 11th World Congress by Dr. Michael Oh of the Department of Neurosurgery at the Allegheny General Hospital in Pittsburgh, Pa.

14 Jun 2013

Study suggests promising brain-imaging technique to improve diagnoses of people with movement disorders

A new University of Florida study suggests a promising brain-imaging technique has the potential to improve diagnoses for the millions of people with movement disorders such as Parkinson's disease.

14 Jun 2013

International experts formulate guidance for neuromodulation practitioners

An international panel of experts has formulated guidance for neuromodulation practitioners that reflects increasing recognition of the value of this growing field.

10 Jun 2013

Blocking MHCII action rescues nerve cells from Parkinson's disease mechanisms, researchers find

The same mechanism that lets the immune system mount a massive attack against invading bacteria contributes to the destruction of brain cells as part of Parkinson's disease, according to a study published online today in the Journal of Neuroscience.

5 Jun 2013

Kinesia ProView™ launched to visualize motor symptom severity response to deep brain stimulation (DBS) in Parkinson’s patients

Great Lakes NeuroTechnologies announced today the product launch of Kinesia ProView™ to visualize motor symptom severity response during programming of deep brain stimulation (DBS) for Parkinson’s disease. Kinesia ProView provides a standardized platform to quantitatively assess how symptoms such as tremor, bradykinesia, and dyskinesias change in response to specific DBS settings during outpatient programming procedures.

15 May 2013

Nicotine in peppers and tomatoes may provide protective effect against Parkinson's disease

New research reveals that Solanaceae-a flowering plant family with some species producing foods that are edible sources of nicotine-may provide a protective effect against Parkinson's disease. The study appearing today in Annals of Neurology, a journal of the American Neurological Association and Child Neurology Society, suggests that eating foods that contain even a small amount of nicotine, such as peppers and tomatoes, may reduce risk of developing Parkinson's.

9 May 2013

BD receives FDA approval for second prefilled injectable drug

BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD, announced today that the U.S. Food and Drug Administration has approved the second drug to be offered in the recently launched BD Simplist line of ready-to-administer prefilled generic injectables.

From BD (Becton, Dickinson and Company) 24 Apr 2013

Movement Disorder News and Research

Latest Movement Disorder News and Research

Exercise program improves symptoms of depression in patients with Parkinson's disease

VISIUS iMRI and ClearPoint guidance platform make DBS surgery an option for children with dystonia

Henry Ford offers electric stimulation of brain using FDA-approved device for hard-to-treat epilepsy cases

Boston Scientific gets CE Mark approval for Vercise Deep Brain Stimulation System

InSightec: First patient treated in ExAblate Neuro Phase III pivotal trial for tremor

GLNT integrates video conferencing technology into Kinesia HomeView for Parkinson’s disease patients

Parkin protein plays key role in destruction of bacteria that cause tuberculosis

Scientists identify new drugs that have potential to slow down progression of Parkinson's

Alzheimer’s drug trial: an interview with Geoffrey Kempler, Chairman & CEO Prana Biotechnology

Navidea Biopharmaceuticals signs SPA agreements with FDA for NAV5001 Phase 3 program

Researcher discovers potential explanation for shizophrenia symptoms

Great Lakes NeuroTechnologies receives patent for Parkinson’s disease monitoring technology

Experts report lasting benefits of deep brain stimulation in patients with hereditary dystonia

Research: Deep brain stimulation is associated with weight loss trend in morbidly obese patients

Study suggests promising brain-imaging technique to improve diagnoses of people with movement disorders

International experts formulate guidance for neuromodulation practitioners

Blocking MHCII action rescues nerve cells from Parkinson's disease mechanisms, researchers find

Kinesia ProView™ launched to visualize motor symptom severity response to deep brain stimulation (DBS) in Parkinson’s patients

Nicotine in peppers and tomatoes may provide protective effect against Parkinson's disease

BD receives FDA approval for second prefilled injectable drug

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Movement Disorder News and Research

Latest Movement Disorder News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in